STOCK TITAN
  1. Home
  2. Sec-filings
  3. AAPG
  4. [6-K] ASCENTAGE PHARMA GROUP INTERNATIONAL Current Report (Foreign Issuer)

Ascentage Pharma (NASDAQ: AAPG) plans participation in three upcoming investor conferences

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Ascentage Pharma Group International furnished a Form 6-K to share a press release announcing that its management is scheduled to participate in three upcoming investor conferences. Webcasts of a fireside chat and presentation will be available through the Events page of the company’s Investor Relations website.

The filing also reiterates that Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on novel cancer therapies, with two approved products in China and multiple ongoing global registrational Phase III trials across leukemia, lymphoma, acute myeloid leukemia, higher-risk myelodysplastic syndromes, and other tumor types.

Positive

  • None.

Negative

  • None.
Investor conferences three conferences management scheduled to participate
Phase III POLARIS trials three trials POLARIS-1, POLARIS-2, POLARIS-3 for CML, Ph+ ALL, SDH-deficient GIST
GLORA Phase III trials four trials GLORA, GLORA-2, GLORA-3, GLORA-4 for CLL/SLL, AML, higher-risk MDS
Form 20-F year-end December 31, 2025 referenced Annual Report on Form 20-F
Hong Kong IPO prospectus date October 16, 2019 prospectus date for Hong Kong initial public offering
global registrational Phase III trial medical
"is currently conducting an FDA-cleared global registrational Phase III trial, called POLARIS-2, of Olverembatinib"
BCR-ABL1 inhibitor medical
"Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China"
National Reimbursement Drug List (NRDL) regulatory
"It is covered by the China National Reimbursement Drug List (NRDL)."
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) medical
"for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)"
forward-looking statements regulatory
"This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Form 6-K: How Foreign Companies Report to the SEC →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of May 2026

 

Commission File Number: 001-42484

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

  

 

 

 

 

EXPLANATORY NOTE

 

On May 12, 2026, Ascentage Pharma Group International issued a press releases entitled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences”. A copy of the press release is furnished as Exhibit 99.1.

 

1

 

 

INDEX TO EXHIBITS

 

Exhibit    
Number   Exhibit Title
     
99.1   Press Release dated May 12, 2026

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ASCENTAGE PHARMA GROUP INTERNATIONAL
   
Date: May 12, 2026 /s/ Dajun Yang
  Name: Dajun Yang
  Title: Chief Executive Officer

 

 

3

 

 

Exhibit 99.1

 

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

 

ROCKVILLE, MD. and SUZHOU, China, May 12, 2026 -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management is scheduled to participate in three upcoming investor conferences.

 

·B. Riley Commercial/Late-Stage Oncology Best Ideas Summit: One-on-one meetings on May 18th

 

·Stifel 2026 Virtual Targeted Oncology Forum: One-on-one meetings and fireside chat at 10:30 am EDT on May 19th

 

·Jefferies Global Healthcare Conference in New York: One-on-one meetings and presentation at 8:10 am EDT on June 3rd

 

The webcasts for the fireside chat and presentation can be accessed by visiting the Events page in the Investor Relations section of Ascentage Pharma’s website.

 

About Ascentage Pharma Group International

 

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

 

The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first- and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared global registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

  

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

 

 

 

 

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

 

Cautionary Note Regarding Forward-Looking Statements


This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions, or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risks Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited, where the Company’s ordinary shares are listed, it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

 

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contacts
Investor Relations:

Stella Yang

Ascentage Pharma

Stella.Yang@ascentage.com

+1 (301) 792-6286

 

Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282

 

Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012

 

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What does Ascentage Pharma (AAPG) announce in this Form 6-K?

Ascentage Pharma reports that its management will participate in three upcoming investor conferences. The company notes that webcasts of a fireside chat and presentation will be accessible via the Events page in the Investor Relations section of its official website for interested stakeholders.

What type of company is Ascentage Pharma (AAPG) and what is its focus?

Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on discovering, developing and commercializing novel, differentiated cancer therapies. Its pipeline includes inhibitors targeting Bcl-2 and MDM2-p53, next-generation kinase inhibitors and protein degraders designed to address unmet medical needs in oncology.

Which approved products does Ascentage Pharma (AAPG) currently have in China?

Ascentage Pharma has two approved products in China: Olverembatinib, a third-generation BCR-ABL1 inhibitor for various CML indications, and Lisaftoclax, a Bcl-2 inhibitor approved for adults with CLL/SLL previously treated with systemic therapy including Bruton’s tyrosine kinase inhibitors.

What late-stage clinical trials is Ascentage Pharma (AAPG) conducting?

Ascentage Pharma is conducting multiple global registrational Phase III trials, including POLARIS-1, POLARIS-2 and POLARIS-3 for CML, Ph+ ALL and SDH-deficient GIST, plus four GLORA studies evaluating Lisaftoclax in CLL/SLL, AML and newly diagnosed higher-risk myelodysplastic syndromes.

Which major partners and institutions collaborate with Ascentage Pharma (AAPG)?

Ascentage Pharma has global partnerships and relationships with companies such as Takeda, AstraZeneca, Merck, Pfizer and Innovent. It also collaborates with leading institutions including Dana-Farber Cancer Institute, Mayo Clinic, the U.S. National Cancer Institute and the University of Michigan on research and development efforts.

Where are Ascentage Pharma’s (AAPG) shares listed and what filings are referenced?

Ascentage Pharma’s ordinary shares are listed on The Stock Exchange of Hong Kong, and its ADSs trade on Nasdaq. The press release references its Annual Report on Form 20-F for the year ended December 31, 2025, and the Hong Kong IPO prospectus dated October 16, 2019.

Filing Exhibits & Attachments

1 document

Press Releases